Xellia Pharmaceuticals has acquired Fresenius Kabi’s lyophilized vial manufacturing facility in Raleigh, North Carolina. The manufacturing site is Xellia’s first facility in the U.S., expanding the company’s manufacturing capacity for injectable pharmaceutical products. The deal includes a continuous manufacturing and supply agreement with Fresenius Kabi USA.
Xellia intends to retain the approximately 80 staff members currently employed at the site and will continue to manufacture certain products for Fresenius Kabi. In the future, the company plans to employ more staff as it further expands the site.
Xellia said it is increasingly moving on from its origins as a manufacturer of active pharmaceutical ingredients to better serve its global customer base of over 500 pharmaceutical companies by supplying the finished dosage form of its drugs.
“We have great respect for Fresenius Kabi and its employees, and have been in partnership with the company for years as a preferred, trusted supplier of active pharmaceutical ingredients,” said Carl-Åke Carlsson, CEO of Xellia. “I believe this acquisition will be a win-win situation, benefiting both companies and our customers.”
“This agreement is part of our global strategy to optimize our manufacturing and supply network,” said John Ducker, president and CEO of Fresenius Kabi USA. “Both companies are committed to assure a smooth and seamless transition for customers and employees. This transaction will have no impact on Fresenius Kabi’s ability to meet customer demand for the products we currently manufacture at the Raleigh site and we continue to work closely with the FDA to alleviate U.S. drug shortages.”
The acquisition is part of the latest phase of Xellia’s on-going global expansion plans, which include an investment of $2 million at the company’s Product and Innovation R&D Centre of Excellence in Zagreb, Croatia in May.